This is a virtual panel discussion about whether biosimilars—cheaper copies of expensive biologic drugs—have finally gained enough market traction to meaningfully lower drug costs. The speakers explore what's working, what's broken in the system, and what comes next as more blockbuster drugs face biosimilar competition.

• The first wave of biosimilars has launched, with more major drugs facing lower-cost competition soon
• The FDA has been removing regulatory barriers to speed biosimilar approvals in an effort to reduce drug spending
• Policy shifts and structural problems in the healthcare system could derail the cost-savings momentum biosimilars have built